Karyopharm Therapeutics (KPTI) Announces Initiation Of A Phase 1 Study Of Decitabine (Dacogen®) And Selinexor (KPT-330) In Acute Myeloid Leukemia (AML)
4/16/2014 9:32:40 AM
NATICK, Mass., April 15, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 1 combination trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in combination with the DNA methylation inhibitor decitabine (Dacogen®) in patients with relapsed or refractory acute myeloid leukemia (AML) and in patients age =60 years with newly diagnosed AML. The study is being conducted at The Ohio State University Comprehensive Cancer Center under the direction of principal investigator Ramiro Garzon, MD, Associate Professor.
Help employers find you! Check out all the jobs and post your resume.
comments powered by